PL377696A1 - Enancjomery pochodnych kwasu tiofenohydroksamowego i ich zastosowanie jako inhibitorów HDAC - Google Patents

Enancjomery pochodnych kwasu tiofenohydroksamowego i ich zastosowanie jako inhibitorów HDAC

Info

Publication number
PL377696A1
PL377696A1 PL377696A PL37769603A PL377696A1 PL 377696 A1 PL377696 A1 PL 377696A1 PL 377696 A PL377696 A PL 377696A PL 37769603 A PL37769603 A PL 37769603A PL 377696 A1 PL377696 A1 PL 377696A1
Authority
PL
Poland
Prior art keywords
enantiomers
acid derivatives
hydroxamic acid
hdac inhibitors
thiophene hydroxamic
Prior art date
Application number
PL377696A
Other languages
English (en)
Inventor
Adelbert Grossmann
Frank Herting
Matthias Koerner
Klaus-Peter Kuenkele
Anja Limberg
Olaf Mundigl
Ulrich Tibes
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL377696A1 publication Critical patent/PL377696A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
PL377696A 2002-12-16 2003-12-15 Enancjomery pochodnych kwasu tiofenohydroksamowego i ich zastosowanie jako inhibitorów HDAC PL377696A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02028038 2002-12-16

Publications (1)

Publication Number Publication Date
PL377696A1 true PL377696A1 (pl) 2006-02-06

Family

ID=32524005

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377696A PL377696A1 (pl) 2002-12-16 2003-12-15 Enancjomery pochodnych kwasu tiofenohydroksamowego i ich zastosowanie jako inhibitorów HDAC

Country Status (18)

Country Link
US (1) US7098241B2 (pl)
EP (1) EP1575933A1 (pl)
JP (1) JP2006513181A (pl)
KR (1) KR100781929B1 (pl)
CN (1) CN100391954C (pl)
AR (1) AR042459A1 (pl)
AU (1) AU2003293882A1 (pl)
BR (1) BR0317348A (pl)
CA (1) CA2507629A1 (pl)
CL (1) CL2003002611A1 (pl)
GT (1) GT200300285A (pl)
PA (1) PA8592101A1 (pl)
PE (1) PE20040913A1 (pl)
PL (1) PL377696A1 (pl)
RU (1) RU2348625C2 (pl)
TW (1) TW200418825A (pl)
UY (1) UY28127A1 (pl)
WO (1) WO2004054999A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002344854B2 (en) * 2001-06-11 2008-11-06 Vertex Pharmaceuticals (Canada) Incorporated Thiophene derivatives as antiviral agents for flavivirus infection
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN100413861C (zh) 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
CN1980920A (zh) * 2004-06-14 2007-06-13 霍夫曼-拉罗奇有限公司 噻吩衍生物、它们的制备以及作为药剂的应用
CN1964963A (zh) * 2004-06-14 2007-05-16 霍夫曼-拉罗奇有限公司 异羟肟酸酯、它们的制备以及作为药剂的应用
JP2008501665A (ja) * 2004-06-14 2008-01-24 エフ.ホフマン−ラ ロシュ アーゲー チオフェンヒドロキサム酸誘導体及びhdac阻害剤としてのこれらの使用
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN101218224B (zh) * 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0522130D0 (en) * 2005-10-31 2005-12-07 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PT2104674E (pt) 2006-11-15 2013-07-26 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infeções por flavivírus
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011106627A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012019772A1 (en) * 2010-08-12 2012-02-16 Institut De Recherche Pour Le Developpement (I.R.D) Method for treating protozoan parasitic diseases
US20140107166A1 (en) * 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
CA2850757A1 (en) * 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
JP6208603B2 (ja) 2013-03-15 2017-10-04 日本たばこ産業株式会社 ピラゾール−アミド化合物およびその医薬用途
CN103159646B (zh) * 2013-03-19 2014-10-22 广东药学院 一种异羟肟酸类化合物及其制备方法和应用
CA2933907A1 (en) 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
JP7036724B2 (ja) 2016-07-29 2022-03-15 日本たばこ産業株式会社 ピラゾール-アミド化合物の製造方法
CN116120300B (zh) * 2023-02-21 2024-10-15 贵州大学 一种含异羟肟酸片段的嘧啶类化合物其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE661226A (fr) 1965-03-17 1965-09-17 Acides arylacethydroxamiques, amides correspondants et procedes de preparation.
NL6406688A (pl) 1964-06-05 1965-12-06
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
NL7614113A (nl) 1976-12-18 1978-06-20 Akzo Nv Hydroxamzuren.
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
JPS5436229A (en) 1977-08-25 1979-03-16 Hokuriku Pharmaceutical Substituted acetohydroxam derivative
JPS57145838A (en) 1981-03-05 1982-09-09 Hodogaya Chem Co Ltd P-benzyloxybenzoic acid derivative and herbicide containing the same
JPS57149254A (en) 1981-03-10 1982-09-14 Hodogaya Chem Co Ltd M-benzyloxybenzamide derivative and herbicide containing the same
GB8320702D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agents
US4769461A (en) 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
GB8728051D0 (en) 1987-12-01 1988-01-06 Leo Pharm Prod Ltd Chemical compounds
JPH01216961A (ja) 1988-02-25 1989-08-30 Takeda Chem Ind Ltd 12−リポキシゲネース阻害剤
DE3903989A1 (de) 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
US5091533A (en) 1990-03-12 1992-02-25 Merck Frosst Canada, Inc. 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
JPH04217950A (ja) 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤
JPH03291264A (ja) 1990-04-06 1991-12-20 Japan Tobacco Inc ジメチルアニリン誘導体、その製造方法及びそれを有効成分として含有するガン細胞分化誘導検査試薬及び制癌剤
JPH04187666A (ja) 1990-11-20 1992-07-06 Asahi Chem Ind Co Ltd シクロヘキサンカルボン酸アミド誘導体及び酵素阻害剤ならびに抗潰瘍剤
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP0544166A3 (en) 1991-11-26 1993-11-03 Hoffmann La Roche Cephalosporinderivatives
CA2139325A1 (en) 1992-07-16 1994-02-03 Stephen E. Bales Thiodiphenol copolycarbonates and their use as components of multilayered polymeric reflective bodies
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6008257A (en) 1994-01-28 1999-12-28 Bayer Aktiengesellschaft Hydroxamic-acid derivatives, method of preparing them and their use as fungicides
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
KR100430059B1 (ko) 1995-04-10 2004-09-24 후지사와 야꾸힝 고교 가부시키가이샤 cGMP-PDE억제제로서의인돌유도체
US5786358A (en) 1995-09-08 1998-07-28 The Trustees Of Princeton University Pyridopyrimidines as nonclassical antifolates
WO1997012903A1 (en) 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
FR2746098B1 (fr) 1996-03-14 1998-04-30 Composes propynyl biaromatiques
AUPO118896A0 (en) 1996-07-23 1996-08-15 Fujisawa Pharmaceutical Co., Ltd. New use
RU2171250C2 (ru) 1996-08-05 2001-07-27 Пролинкс, Инк. Производные 2,6-дигидрокси-4-аминометилбензоата
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JPH10114654A (ja) 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
AU743901B2 (en) 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
US6392010B1 (en) 1996-12-19 2002-05-21 Aventis Pharmaceuticals Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
JPH10182583A (ja) 1996-12-25 1998-07-07 Mitsui Chem Inc 新規ヒドロキサム酸誘導体
ATE292622T1 (de) 1997-01-22 2005-04-15 Aventis Pharma Inc Substituierte beta-thiocarbonsäuren
GEP20022626B (en) 1997-02-27 2002-02-25 American Cyanamid Company Us N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
JPH10287634A (ja) 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
CA2293433C (en) 1997-06-17 2009-09-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
JP4125868B2 (ja) 1997-09-09 2008-07-30 塩野義製薬株式会社 4−置換安息香酸誘導体およびそれを有効成分として含有する制癌剤
DK1021413T3 (da) 1997-10-06 2003-10-06 Wyeth Corp Fremstilling og anvendelse af ortho-sulfonamido-bicykliske heteroarylhydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
JP2001519410A (ja) 1997-10-15 2001-10-23 アメリカン・ホーム・プロダクツ・コーポレイション 新規なアリールオキシ−アルキル−ジアルキルアミン
ID25639A (id) 1998-02-19 2000-10-19 American Cyanamid Co Alkil, aril atau heteroarilamida tersubstitusi n-hidroksi-2-(alkil, aril, atau heteroaril sulfanil, sulfinil atau sulfonil)-3 sebagai inhibitor matriks mataloproteinase
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
US6784173B2 (en) * 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
WO2003055479A1 (en) * 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3

Also Published As

Publication number Publication date
KR20050089157A (ko) 2005-09-07
RU2005122447A (ru) 2006-05-27
CA2507629A1 (en) 2004-07-01
BR0317348A (pt) 2005-11-16
AU2003293882A1 (en) 2004-07-09
CL2003002611A1 (es) 2005-01-14
UY28127A1 (es) 2004-06-30
CN1726204A (zh) 2006-01-25
JP2006513181A (ja) 2006-04-20
AR042459A1 (es) 2005-06-22
PE20040913A1 (es) 2005-01-18
CN100391954C (zh) 2008-06-04
US7098241B2 (en) 2006-08-29
US20040122079A1 (en) 2004-06-24
WO2004054999A1 (en) 2004-07-01
GT200300285A (es) 2004-07-14
KR100781929B1 (ko) 2007-12-04
EP1575933A1 (en) 2005-09-21
RU2348625C2 (ru) 2009-03-10
PA8592101A1 (es) 2004-11-02
TW200418825A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
IL164002A0 (en) Sulfonyl-derivatives as novel inhibitors of histone deacetylase
IL164003A0 (en) Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
IL164659A0 (en) Inhibitors of histone deacetylase
PL378181A1 (pl) Pochodne kwasu hydroksamidowego jako inhibitory deacetylazy histonowej (HDAC)
EG25655A (en) Benzamide derivatives useful as histone deacetylase inhibitors
AU2003215112A8 (en) Novel bicyclic hydroxamates as inhibitors of histone deacetylase
IL159097A0 (en) Aromatic hydroxamic acid derivatives useful as hdac inhibitors
AU2003219595A8 (en) Alpha,beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
PL374970A1 (pl) Podstawione kwasy tienylo-hydroksamowe jako inhibitory deacetylazy histonowej
EP1735319A4 (en) Histone deacetylase INHIBITORS
EP1755601A4 (en) HISTONE DEACETYLASE INHIBITORS
AU2003303128A8 (en) Inhibitors and methods of use thereof
EP1567142A4 (en) TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
EP1677731A4 (en) THIOPHENE AND BENZOTHIOPHENE DERIVATIVES OF HYDROXAMIC ACID
EP1496896A4 (en) AKT INHIBITORS EFFECT
EP1496906A4 (en) HEMMER OF ACT ACTIVITY
IL165910A0 (en) Compositions of hyaluronic acid and methods of use
AU2003286249A8 (en) Histone deacetylase inhibitors
EP1771167A4 (en) Histone deacetylase INHIBITORS:
PL371217A1 (pl) Inhibitory integryny alfaVbeta6
EP1503749A4 (en) METHIONINE INHIBITORS AMINOPEPTIDASE-2 AND METHODS OF USE THEREOF
IL164267A0 (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
AU2003277878A1 (en) Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
SG107315A1 (en) Use of conjugated linoleic acid derivatives
GB0418435D0 (en) HDAC inhibitors and methods of use thereof

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)